Health care and life sciences companies and their investors rely on Brian to navigate complex regulatory, transactional, strategic, and enforcement matters with pragmatic, business-focused solutions. He provides strategic counsel on federal and state compliance, leads regulatory due diligence processes in transactions, and defends companies facing government audits and investigations.
Experience
Representative matters
Representative matters
Lead regulatory counsel to InTandem Capital Partners and its leading ambulatory infusion therapy company, Vivo Infusion, in its acquisition of Neurology Institute of San Antonio and Vista Infusions.
Lead regulatory counsel to InTandem Capital Partners and its personal care platform, HouseWorks Holdings, LLC, in its acquisition of the Connecticut Personal Care Division from AccordCare.
Lead regulatory counsel to InTandem Capital Partners, a health care services-focused private equity firm, in its strategic investment in Houseworks, a leading provider of personal care services in Massachusetts, New Hampshire, Pennsylvania, and Maine. Brian’s representation includes several other additions to the Housework’s platform, including the acquisition of the personal care division at Amedisys.
Lead regulatory counsel to InTandem Capital Partners and its leading ambulatory infusion therapy company, Vivo Infusion, in its acquisition of Neurology Institute of San Antonio and Vista Infusions.
Lead regulatory counsel to InTandem Capital Partners and its personal care platform, HouseWorks Holdings, LLC, in its acquisition of the Connecticut Personal Care Division from AccordCare.
Lead regulatory counsel to InTandem Capital Partners, a health care services-focused private equity firm, in its strategic investment in Houseworks, a leading provider of personal care services in Massachusetts, New Hampshire, Pennsylvania, and Maine. Brian’s representation includes several other additions to the Housework’s platform, including the acquisition of the personal care division at Amedisys.
Lead regulatory counsel to InTandem Capital Partners, a health care services-focused private equity firm, in its strategic development of an ambulatory infusion services platform. Brian’s representation includes the formation of Vivo Infusion, now one of the country’s largest ambulatory services providers. Notable transactions include the acquisition of CIVIC Infusion; Infusion Center of Pennsylvania, the largest nonhospital infusion provider in Philadelphia; and Specialty Infusion Centers.
Lead regulatory counsel for private equity and growth capital firm – with over $100 billion in managed assets – in its bid to take a large public health care company private.
Lead regulatory counsel for private equity investment firm on its acquisition of California-based fertility practices.
Lead counsel for private equity backed portfolio provider and its management company in a voluntary disclosure to the HHS-OIG.
Lead regulatory counsel for private equity investment firm on its financing of a complex buyout and restructuring of a physician management and radiation oncology services company.
Counsel to a hospice services entity in a complex post-sale dispute with a private equity-backed national hospice company. After buyer self-disclosed to HHS-OIG and sued the seller in arbitration for the proposed settlement amount with HHS-OIG, Brian persuaded OIG that its client was the party of interest and negotiated a resolution with OIG for almost $10 million less than originally proposed.
Long-standing outside regulatory and fraud and abuse counsel to Fortune 100 global medical device, durable medical equipment, and health care corporation.
Serves as regulatory counsel to global orthopedics company.
Serves as regulatory counsel to Fortune 500 global company involved in distribution of medical products.
Served as regulatory counsel for medical device company as it prepared for market entry after receiving clearance of its device from the U.S. Food and Drug Administration.
Served as regulatory and compliance counsel to pharmaceutical manufacturer with a rare disease drug. Representation included advising the manufacturer on its go-to-market commercial strategy in the United State to ensure compliance with various federal and state laws.
Represented European-based digital therapeutics company on its market access strategy in the United States. Representation included negotiating large affiliation agreements with Pfizer, AstraZeneca, Eli Lilly, and Anthem.
Lead counsel for Fagron Holding USA LLC and its wholly owned subsidiaries in a global settlement with the DOJ based on two False Claims Act cases alleging inflated average wholesale prices, kickbacks to physicians, and waivers of co-pay. United States ex rel. Hueseman v. PSI et al., (WDTX) and United States ex rel. Sten v. Midwest Compounders et al., (NDIA).
Counsel to pharmaceutical manufacturer in restructuring of its corporate compliance program.
On behalf of a medical device corporation, conducted comprehensive review of its corporate compliance program.
Lead counsel for a large pharmacy benefit manager in two separate investigations under the FCA, both of which were subsequently closed by the DOJ without any further action.
Successfully secured the dismissal of a False Claims Act (FCA) lawsuit against a Florida-based hospital system and other defendants in the U.S. District Court for the Middle District of Florida. The case involved alleged FCA violations related to Florida’s Low Income Pool (LIP) program, the CARES Act, and the Stark Law. The Court dismissed claims under the public disclosure bar of federal and state FCAs, with some claims dismissed with prejudice, and also rejected the complaint as an impermissible “shotgun pleading."
Lead attorney representing one of the largest non-profit health systems in an appeal of an audit conducted by the Office of Audit Services for the Office of Inspector General to the Department of Health and Human Services. Brian’s representation resulted in a reduction in the original Medicare overpayment determination of more than $8 million to a little under $400,000. Further, Brian’s representation resulted in the government paying monetary interest of approximately $500,000 back to the provider, which is more than what the provider ultimately was liable for after the successful appeal.
Lead counsel to large non-profit health system in complex internal investigation of contractual arrangements with certain cardiology groups that implicated the Stark and Anti-Kickback laws. Representation resulted in a voluntary disclosure to, and favorable settlement with, the Office of Counsel to the Inspector General.
Lead counsel to a large non-profit health system in dissolution of professional services agreement with independent specialty physician practice and subsequent conversion of this physician practice to employment model with health system.
Primary compliance consultant for one of the largest public-owned hospital districts.
Lead counsel for prestigious pediatric hospital in complex investigation involving Stark Law compliance with several independent physician practices. Representation included disclosure to the CMS under its Self-Referral Disclosure Protocol.
Lead counsel to a Special Health Care District serving one of the largest counties in the United States on its comprehensive agreement with the largest multi-specialty physician group in the state covering all clinical, administrative, research, and teaching functions. Representation of this Special Health Care District includes ensuring compliance with this agreement that is valued, minimally, at $150 million/year.
Lead counsel to one of the nation’s largest not-for-profit health plans in an internal investigation of its compliance with network adequacy requirements under Medicare regulations and sub-regulatory guidance.
Lead compliance counsel for large long-term care company operating under a Corporate Integrity Agreement with HHS-OIG.
Representing several non-profit health care systems on hospital-physician compensation structures and alignment, and compliance with reimbursement regulations.
Lead defense counsel for long-term care company in two FCA matters, one of which settled after a protracted multiyear civil and criminal investigation, and another resulting in a declination by both the Department of Justice (DOJ) and the respective State Attorney General’s Offices.
Lead counsel for regional health system resulting in a declination by DOJ of a qui tam alleging false claims based on provider-based billing and 340B program.
Represented numerous entities operating under corporate integrity agreements with HHS-OIG.
Recognitions
- Named to Thomson Reuters’ Stand-Out Lawyers list, 2025
- Recognized in Nashville Medical News, “InCharge Healthcare,” 2017-2020
Credentials
Education
Education
- Washington University in St. Louis School of Law, 2004, J.D., Washington University Law Review, Executive Notes Editor
- Drury University, 1998, B.A.
Professional admissions & qualifications
Professional admissions & qualifications
- Tennessee
- District of Columbia
- Maryland
Professional affiliations
Professional affiliations
- Member, American Health Law Association (AHLA), Fraud & Abuse Practice Group, Advisory Opinion Task Force
- Member, American Bar Association, Health Law Practice Group
News
Media mentions
1 / 2
Insights
Blogs
1 / 2
Events
1 / 7